IBO: רווח נקי למניה (EPS TTM) Impact BioMedical

Low governance transparency and questionable management efficiency are negatively impacting the capitalization of Impact BioMedical Inc (IBO). The current annual net income per share illustrates the business's adaptation to market pressure, where 0.21 shows the current volume of this metric. Diversification through patents for sugar substitutes and antivirals supports the holding, yet the lack of sales and pricing power makes the asset value dependent on investors' valuation of the intellectual property.

Net income per share over 12 months measures the portion of profit attributable to a single common share, neutralizing the effect of equity dilution. For Impact BioMedical Inc (IBO), this indicator reflects the efficiency of patent monetization and the profitability of licensing deals. By analyzing the rolling annual earnings per share, an investor can observe the actual dynamics of intellectual property capitalization. The upward trend of the line confirms the commercial success of antiviral developments, while a stable trend minimizes the risks of asset freezes.